Takafumi Shichijo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takafumi Shichijo has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Jun-Ichirou Yasunaga
Department of Hematology, Rheumatology and Infectious Diseases Kumamoto University Hospital Kumamoto Japan
103 shared publications - Masao Matsuoka
Kumamoto University
99 shared publications - Miho Watanabe
Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University
91 shared publications - Azusa Tanaka
Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
90 shared publications - Osama Hussein
Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
89 shared publications - Kosuke Toyoda
Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University
81 shared publications
Latest Publications
- 26 September 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70272
Impact of Residual Disease Localization Before Allogeneic Hematopoietic Stem Cell Transplantation on Outcomes in Adult T‐Cell Leukemia‐Lymphoma
Allogeneic hematopoietic stem cell transplantation (allo‐HCT) is the only curative approach for adult T‐cell leukemia‐lymphoma (ATL). However, preventing post‐transplant relapse remains challenging. While pre‐transplant disease status is known to be associated with post‐transplant outcomes, the impact of residual disease (RD) localization at the time of allo‐HCT has not been well described. In this retrospective study of 33 patients with aggressive ATL who underwent allo‐HCT, patients were classified into two risk groups based on RD sites: a low‐risk group (no lymph node [LN] or extranodal [EN] disease, regardless of the presence of peripheral blood disease) and a high‐risk group (presence of LN and/or EN disease). The low‐risk group had significantly superior overall survival (OS) and progression‐free survival (PFS) compared to the high‐risk group, with longer median survival times (OS: 1953 vs. 245 days; PFS: 1177.5 vs. 72 days) and higher 2‐year survival rates (OS: 65.0% vs. 11.3%; PFS: 50.0% vs. 8.3%) ( p = 0.012 and p = 0.013, respectively). Furthermore, even among patients who had not achieved complete response, RD localization stratified the survival outcomes: the 2‐year OS and PFS were 75.0% and 75.0% in the low‐risk group, compared with 11.3% and 8.3% in the high‐risk group, respectively. In conclusion, RD localization at the time of allo‐HCT is a novel prognostic factor, highlighting the need for tailored pre‐transplant management for ATL.
- 26 September 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70272
Impact of Residual Disease Localization Before Allogeneic Hematopoietic Stem Cell Transplantation on Outcomes in Adult T‐Cell Leukemia‐Lymphoma
Allogeneic hematopoietic stem cell transplantation (allo‐HCT) is the only curative approach for adult T‐cell leukemia‐lymphoma (ATL). However, preventing post‐transplant relapse remains challenging. While pre‐transplant disease status is known to be associated with post‐transplant outcomes, the impact of residual disease (RD) localization at the time of allo‐HCT has not been well described. In this retrospective study of 33 patients with aggressive ATL who underwent allo‐HCT, patients were classified into two risk groups based on RD sites: a low‐risk group (no lymph node [LN] or extranodal [EN] disease, regardless of the presence of peripheral blood disease) and a high‐risk group (presence of LN and/or EN disease). The low‐risk group had significantly superior overall survival (OS) and progression‐free survival (PFS) compared to the high‐risk group, with longer median survival times (OS: 1953 vs. 245 days; PFS: 1177.5 vs. 72 days) and higher 2‐year survival rates (OS: 65.0% vs. 11.3%; PFS: 50.0% vs. 8.3%) ( p = 0.012 and p = 0.013, respectively). Furthermore, even among patients who had not achieved complete response, RD localization stratified the survival outcomes: the 2‐year OS and PFS were 75.0% and 75.0% in the low‐risk group, compared with 11.3% and 8.3% in the high‐risk group, respectively. In conclusion, RD localization at the time of allo‐HCT is a novel prognostic factor, highlighting the need for tailored pre‐transplant management for ATL.
- Open Access
- 7 January 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (4) , 476-486
Viral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV
Viruses induce approximately 12% of human cancers, including lymphomas. In the case of T/NK cell neoplasms, human T-cell leukemia virus type I (HTLV-1) causes adult T-cell leukemia-lymphoma (ATL), and Epstein-Barr virus (EBV) is associated with extranodal NK/T-cell lymphoma (ENKTCL) and chronic active Epstein–Barr virus disease (CAEBV). Common mechanisms for lymphoma development have been proposed. Viral genes, such as tax and HTLV-1 bZIP factor (HBZ) of HTLV-1, and latent membrane protein 1 (LMP1) and BamHI A rightward transcript microRNA (miRNA-BART) of EBV, contribute to host immune evasion and modulation of host signaling pathways, resulting in the persistence of viral-infected cells. This viral strategy is closely associated with oncogenesis. Furthermore, the long-term survival of infected cells leads to the accumulation of somatic mutations and aberrant epigenetic alterations. These events eventually lead to ATL, ENKTCL, and the lymphoma-like subset of CAEBV. Interrupting these common oncogenic mechanisms is a promising therapeutic strategy for viral-driven lymphomas with poor prognoses.
- 7 January 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (4) , 476-486
Open AccessViral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV
Viruses induce approximately 12% of human cancers, including lymphomas. In the case of T/NK cell neoplasms, human T-cell leukemia virus type I (HTLV-1) causes adult T-cell leukemia-lymphoma (ATL), and Epstein-Barr virus (EBV) is associated with extranodal NK/T-cell lymphoma (ENKTCL) and chronic active Epstein–Barr virus disease (CAEBV). Common mechanisms for lymphoma development have been proposed. Viral genes, such as tax and HTLV-1 bZIP factor (HBZ) of HTLV-1, and latent membrane protein 1 (LMP1) and BamHI A rightward transcript microRNA (miRNA-BART) of EBV, contribute to host immune evasion and modulation of host signaling pathways, resulting in the persistence of viral-infected cells. This viral strategy is closely associated with oncogenesis. Furthermore, the long-term survival of infected cells leads to the accumulation of somatic mutations and aberrant epigenetic alterations. These events eventually lead to ATL, ENKTCL, and the lymphoma-like subset of CAEBV. Interrupting these common oncogenic mechanisms is a promising therapeutic strategy for viral-driven lymphomas with poor prognoses.
- Open Access
- 27 November 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70413
Peripheral Blood CD4 / CD8 Ratio Predicts Out‐of‐Specification Products in Lisocabtagene Maraleucel Manufacturing
Background: Lisocabtagene maraleucel (liso‐cel) is a CD19‐directed chimeric antigen receptor T‐cell therapy for patients with relapsed or refractory large B‐cell lymphoma. Methods: In this retrospective study involving 22 patients, we evaluated the association between peripheral blood CD4/CD8 ratios and the occurrence of out‐of‐specification (OOS) products during manufacturing. Expanded access protocols have permitted the infusion of OOS products, despite their failure to meet commercial release criteria, under close regulatory oversight. Results: Five patients who received OOS products had significantly lower CD4/CD8 ratios (median 0.22 vs. 0.46; p = 0.008). Conclusion: Our findings suggest that a low CD4/CD8 ratio (below one‐third) may be a predictive marker for OOS outcomes, potentially supporting patient selection and treatment planning. Therefore, prospective validation using a larger cohort is warranted.
- 27 November 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70413
Open AccessPeripheral Blood CD4 / CD8 Ratio Predicts Out‐of‐Specification Products in Lisocabtagene Maraleucel Manufacturing
Background: Lisocabtagene maraleucel (liso‐cel) is a CD19‐directed chimeric antigen receptor T‐cell therapy for patients with relapsed or refractory large B‐cell lymphoma. Methods: In this retrospective study involving 22 patients, we evaluated the association between peripheral blood CD4/CD8 ratios and the occurrence of out‐of‐specification (OOS) products during manufacturing. Expanded access protocols have permitted the infusion of OOS products, despite their failure to meet commercial release criteria, under close regulatory oversight. Results: Five patients who received OOS products had significantly lower CD4/CD8 ratios (median 0.22 vs. 0.46; p = 0.008). Conclusion: Our findings suggest that a low CD4/CD8 ratio (below one‐third) may be a predictive marker for OOS outcomes, potentially supporting patient selection and treatment planning. Therefore, prospective validation using a larger cohort is warranted.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Human cluster 2 genes whose H3K27me3 in TSS's was decreased.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Human cluster 2 genes whose H3K27me3 in TSS's was decreased.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Oligonucleotides used in this study.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Oligonucleotides used in this study.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Regulation of TP73 by BATF3 and IRF4.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Regulation of TP73 by BATF3 and IRF4.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Efficacy of the MCT1/4 inhibitor syrosingopine on ATL cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Efficacy of the MCT1/4 inhibitor syrosingopine on ATL cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Experimental reagents and resources with identifiers used in this study.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Experimental reagents and resources with identifiers used in this study.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Transcriptional regulation of SLC16A1 and SLC16A3 by TAp73, and mRNA expression levels of MCT-coding genes among various cancers.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Transcriptional regulation of SLC16A1 and SLC16A3 by TAp73, and mRNA expression levels of MCT-coding genes among various cancers.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Transcriptional regulation by HBZ protein and RNA and the status of TP73 expression.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Transcriptional regulation by HBZ protein and RNA and the status of TP73 expression.